{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-227875","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2026-05-18T11:15:07+00:00","discovered_at":"2026-05-18T11:20:00.357499+00:00","generated_at":"2026-05-18T11:21:25.255362+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Design Therapeutics reports positive Phase 1/2 data for DT-216P2 in Friedreich ataxia","bullets":["After 4 weeks at 1 mpk, mFARS improved 6.4 points, Upright Stability Score 2.7 points, fatigue >5 points (PROMIS).","Whole blood FXN mRNA increased 65% (p<0.001); muscle FXN mRNA up 42% (p=0.015); FXN protein increased 22-27%.","DT-216P2 well-tolerated; no serious adverse events or discontinuations; mild-moderate transient ALT elevations in 3 patients.","Company plans to pursue registrational path; update expected in Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-227875","json":"https://secwatch.observer/filing/0001193125-26-227875.json","markdown":"https://secwatch.observer/filing/0001193125-26-227875.md","text":"https://secwatch.observer/filing/0001193125-26-227875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526227875/0001193125-26-227875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526227875/d154773d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T11:21:25.255362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}